Wellgistics Health Announces Preliminary Inclusion in the Russell 2000 and Russell 3000 Indexes
TAMPA, FLORIDA / ACCESS Newswire / May 29, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a healthcare infrastructure company transforming the prescription drug ecosystem, today announced its preliminary inclusion in the Russell 2000 and Russell 3000 Indexes, as part of the 2025 Russell US Indexes annual reconstitution. FTSE Russell released the preliminary list of additions and deletions to the Russell 2000 and Russell 3000 Indexes on Friday, May 23, with final inclusion expected to take effect following the close of the U.S. equity market on Friday, June 27, 2025.
The Russell 3000 Index encompasses the 3,000 largest U.S. companies by market capitalization, representing approximately 98% of the investable U.S. equity market. The Russell 2000 Index is a subset of the Russell 3000, measuring the performance of the small-cap segment. These indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
"Wellgistics Health's preliminary inclusion in the Russell 2000 and Russell 3000 indexes marks an important milestone in our company's journey," said Brian Norton, CEO of Wellgistics Health. "This recognition enhances our visibility among the broader investment community, supports increased institutional interest and ownership in our stock, and serves as strong validation of our team's ability to execute on our business plan and drive value to our shareholders."
About Wellgistics Health
Wellgistics Health, Inc. is a publicly traded healthcare infrastructure company redefining how medications move, are priced, and reach patients. The company operates across pharmaceutical distribution, prescription technology, and clinical fulfillment-connecting over 150 direct manufacturer contracts to a nationwide network of over 6,000 independent pharmacies.
Wellgistics Health provides real-time prescription hub services, compliance-driven logistics, and patient-first fulfillment solutions, while equipping pharmacies with integrated financial, clinical, and digital tools. Its end-to-end platform supports a broad range of therapeutic areas from specialty-lite to chronic maintenance medications by eliminating friction, accelerating reimbursements, and enabling direct, transparent connections between manufacturers, providers, pharmacies, and patients.
For more information, visit www.wellgisticshealth.com.
Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health's statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans, including without limitation its plan in connection with certain financings and cryptocurrencies and outlook and actions with respect to incurring future expenses. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, which are available for review at www.sec.gov.
For more information, please contact:
Media Contact: media@wellgisticshealth.comInvestor Relations: investors@wellgisticshealth.com
Investor Relations Contact:Skyline Corporate Communications Group, LLCScott Powell, President1177 Avenue of the Americas, 5th FloorNew York, NY 10036Office: (646) 893-5835Email: info@skylineccg.com
SOURCE: Wellgistics Health, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
NMP Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering
Palo Alto, California, June 30, 2025 (GLOBE NEWSWIRE) — NMP Acquisition Corp. (the 'Company') today announced the pricing of its initial public offering of 10,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one right. Each right entitles the holder to receive one-fifth (1/5) of one Class A ordinary share upon consummation of the Company's initial business combination. In connection with the offering, $10.00 per unit will be deposited into a trust account with Continental Stock Transfer & Trust Company acting as trustee. Up to $300,000 of interest earned on the funds held in the trust account, in the aggregate, may be released to us to fund our working capital requirements. In addition, we may withdraw interest earned on the trust to pay our income and franchise taxes, if any. The units are expected to trade on the Nasdaq Global Market ('Nasdaq') under the ticker symbol 'NMPAU' beginning on July 1, 2025. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to trade on Nasdaq under the symbols 'NMP' and 'NMPAR,' respectively. Maxim Group LLC is acting as the sole book-running manager for the offering. The Company has granted the underwriter a 45-day option to purchase up to 1,500,000 additional units at the initial public offering price less the underwriting discount to cover over-allotments, if any. The offering is expected to close on July 2, 2025, subject to customary closing conditions. A registration statement on Form S-1 (File No. 333-286985) (the 'Registration Statement') relating to the securities to be sold in the initial public offering, as amended, was declared effective by the U.S. Securities and Exchange Commission (the 'SEC') on June 30, 2025. The offering is being made only by means of a prospectus. When available, copies of the prospectus relating to this offering may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Syndicate Department, by telephone at (212) 895-3745 or by email at [email protected], or by accessing the SEC's website, This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About NMP Acquisition Corp. NMP Acquisition Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Forward-Looking Statements This press release contains statements that constitute 'forward-looking statements,' including with respect to the Company's initial public offering and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related preliminary prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Contact Information NMP Acquisition FigueroaCEOAttn: Investor Relations E-mail: mailto:[email protected]
Business Upturn
2 hours ago
- Business Upturn
Oliveda International, Inc. (OLVI) Subsidiary Olive Tree People Canada Inc. Brings Its Waterless Beauty to Canada in July 2025
SANTA MONICA, CA, June 30, 2025 (GLOBE NEWSWIRE) — Oliveda International, Inc. (OTC Pink: OLVI) today announced that after a true waterless beauty movement emerged in the United States within just two years, with over 60,000 waterless beauty consultants, and Olive Tree People USA Inc. exploded from 40 to over 10,000 packages per day and up to 4 million in sales per day in 2024 alone, olive farmer and CEO Thomas Lommel has set the course for global expansion by establishing subsidiaries in Canada and Europe. Olive Tree People Canada Inc., based in Edmonton, Alberta, will begin its pre-launch phase in Canada in July 2025, and in October 2025, Olive Tree People Europe AG, based in Switzerland, will drive expansion in Europe. As the Los Angeles Times reported in May 2025, Olive Tree People Inc. is the fastest-growing waterless beauty company in the U.S. With sales of $105 million in its second year, Olive Tree People is growing 600% faster than Beautycounter in its second year and also grew faster than many established celebrity brands such as JLO Beauty and many others. When asked about the secret to its success, olive farmer and CEO Thomas Lommel replied, 'It took me over 21 years to realize that direct-to-consumer sales, rather than retail, is the perfect match for waterless beauty. No marketing campaign in the world – not even the largest campaign and not the most exclusive retail stores – can communicate and deliver waterless beauty more successfully than our waterless beauty consultants in the U.S., and soon in Canada and Europe.' When asked why, Mr. Lommel replied, 'It's simple: They breathe waterless beauty 24/7. Our waterless beauty consultants don't sell; they educate. In so-called Waterless Glow workshops, interested customers learn all about waterless beauty and how it differs from conventional cosmetics. Most of them decide to try us when they hear we offer a 365-day satisfaction guarantee. Many of them come back and buy more products. We've been educating women and men in retail for 21 years, and I can tell you, that's not possible in retail. The women and men on the shelves in retail stores do an excellent job, but they are responsible for dozens of brands and therefore, can't do what our Waterless Beauty consultants 24/7. That's why, after more than 20 years, we are also pursuing a direct-to-consumer approach in Europe with the goal of informing and educating the 448 million women in Europe. We couldn't be prouder of our Waterless Beauty Consultants and therefore, regularly celebrate them in magazines like the Time issue 'Women of the Year,' Vogue USA, or in June 2025, in Vanity Fair , and many others.' Mr. Lommel explained why Waterless Beauty, with over $22 billion, is the fastest-growing segment of the entire beauty industry, 'People understand that Waterless Beauty is the next, and most importantly, true, clean beauty, and they understand that what they wouldn't drink/eat (water with preservatives and refined oils, or even worse, petroleum) shouldn't be applied to their skin either.' When asked about the fact that Olive Tree People is currently valued at over $1 billion, as reported by the LA Times , Mr. Lommel replied, 'I believe that the value of a tree cannot be measured in dollars, and we have saved more than 31,000 of these hundred-year-old and older trees over the past 21 years, and we are the biggest conservationist in the region. I think we humans need to become more humble and realize that we couldn't exist without these trees, not to mention the treasures they give us each year through their harvest. We're probably the first company ever to work with trees, from Tree to Beauty, to reach a valuation of over a billion dollars. However, it was never my goal, and to be honest, it should be much more, given the innovations we've achieved over the past 21 years and the global innovations and new brands that from Tree to Beauty will be launching in 2025.' About Oliveda International, Inc. Oliveda International, Inc. and its subsidiary, Olive Tree People Inc., as well as the European companies, Olive Tree People Europe AG and Oliveda Deutschland GmbH, as well as Olive Tree Farmers SL, were founded by the German real estate investor Thomas Lommel and have more than 20 years of experience in management and organic certification growing mountain olive trees, in the extraction of first-class, internationally award-winning extra virgin olive oils, the extraction of hydroxytyrosol, and in the production and distribution of cosmetic and holistic waterless products related to the olive tree. Lommel is the inventor of the Olive Tree Therapy 10 years in 14 days as well as the inventor of olive matcha, which is based on the ground olive leaf. Also unique is the coffee replacement developed by Lommel, which is based on olive leaf and hydroxytyrosol. In addition, Lommel is successfully active in the rapidly growing mindfulness industry with the olive tree sound bath meditation he developed and the frequencies of his olive trees, which he makes available worldwide. In addition to the registered beauty brands, Oliveda and LA Dope, as well as Re:connected to Nature, The Intuition of Nature, and Olive Mush, to name just a few brands, Lommel is the region's largest conservationist and protector of over 30,000 one-hundred-year-old mountain olive trees, and, with his Thomas Lommel Foundation, he brings the water that he does not use into his waterless beauty products to the people of Africa by building water wells on site. In addition to online sales and a Europe-wide branch network of thousands of retail stores, Oliveda Deutschland GmbH operates its own flagship stores in Berlin and Düsseldorf. The brand's treatment concepts are unique worldwide, and their effectiveness has been confirmed by conventional medicine. Read our book The Olive Tree Therapy 10 Years in 14 Days . Waterless beauty has been called 'The Next Big Thing' in articles in U.S. Vogue , Harper's Bazaar , InStyle , Elle , Madame , Forbes , and many other industry publications, as well as by Mintel, a world-leading futurology institute. Gigi Hadid and many other celebrities are already Oliveda fans and support its success. Further information on Oliveda International, Inc. and its subsidiaries and associate companies and brands can be found at Forward-Looking Statements This press release may contain statements, estimates or projections that constitute 'forward-looking statements' pursuant to the safe harbor provisions of the U.S. federal securities laws. Generally, the words 'believe,' 'expect,' 'intend,' 'estimate,' 'anticipate,' 'project,' 'will' and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties, which may be found in the Company's filings with OTC Markets Group Inc., that could cause actual results to differ materially from the Company's historical experience and present expectations or projections. Investors should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any obligation or intention to publicly update or revise any forward-looking statements unless otherwise required by law. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Indianapolis Star
2 hours ago
- Indianapolis Star
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors Company will also develop a subcutaneous version, PN-477sc, as a once-weekly injection IND-enabling studies underway, with Phase I study initiation expected in 2Q26 Webcast and conference call to be held today at 4:30 pm ET NEWARK, CALIFORNIA / ACCESS Newswire Protagonist Therapeutics, Inc. ('Protagonist' or the 'Company') today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, GCG receptor triple agonist peptide with oral and subcutaneous routes of administration, as a development candidate for the treatment of obesity. The triple agonist PN-477 is designed to offer the optimal combination of total body weight loss, improved gastrointestinal (GI) tolerability and fat to lean mass ratio, with the dosing convenience of a once-daily oral agent and the added optionality of a once-weekly subcutaneous administration. 'We are very pleased to nominate development candidate PN-477, a promising potential best-in class oral GLP-1, GIP, GCG receptor tri-agonist peptide which has demonstrated optimal absolute and relative activity against all three hormone receptors in preclinical testing,' said Dinesh V. Patel, PhD, President and CEO of Protagonist. 'PN-477 is specifically engineered to be orally stable with attention to the relative balance of potencies against the three receptors to potentially leverage their beneficial effects on weight loss and optimal body composition while mitigating their adverse effects. As with our previous drug candidates and late-stage assets, PN-477 is a testament to the power of our peptide technology platform, including the ability to deliver first- and best-in-class targeted oral and injectable peptide therapeutics.' PN-477 has completed extensive preclinical evaluation including oral and metabolic stability, potency, pharmacokinetics and pharmacodynamics studies, and has demonstrated effects in preclinical models of obesity and glycemic control. PN-477 has shown potent in vitro activity in activating the GLP-1, GIP, and GCG receptors. PN-477 also demonstrated robust preclinical proof-of-concept in various animal studies including the diet induced obesity (DIO) preclinical mouse model, normal dogs, and cynomolgus monkeys. Overall, PN-477 has the right balance of potency, oral and in-vivo stability, and pharmacokinetic properties to enable parallel development both as a once-daily oral (PN-477o) and once-weekly injectable (PN-477sc) treatment options. IND enabling studies of PN-477 are underway and initiation of Phase 1 clinical studies is anticipated in the second quarter of 2026. 'While GLP-1 agonists have dominated the market thus far, there remains a broad opportunity for novel therapeutics with better body weight loss, higher ratio of fat to lean mass loss, tolerability and additional beneficial effects in obesity-related comorbidities. A triple GLP-1, GIP, GCG receptor agonist peptide that offers weight loss on par with the best injectable treatments options, as well as the optionality provided by both oral and injectable routes of administration, would be an important therapeutic breakthrough and represents another potential blockbuster drug opportunity for Protagonist,' added Dr. Patel. 'We look forward to moving PN-477 into first-in human clinical Phase 1 studies in the second quarter of 2026.' Conference Call and Webcast Details The dial-in numbers for Protagonist's investor update on Monday, June 30 th at 4:30 pm ET are: US-based Investors: 1-877-407-0752 International Investors: 1-201-389-0912 Conference Call ID: 13754335 The webcast link for the event can be found here: A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event. About Protagonist Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to J&J Innovative Medicines ('JNJ'), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and oral hepcidin. More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of PN-477, and the timing of PN-477 clinical development. In some cases, you can identify these statements by forward-looking words such as 'anticipate,' 'believe,' 'may,' 'will,' 'expect,' or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading 'Risk Factors' contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. Investor Relations Contact Corey Davis, Ph.D. LifeSci Advisors cdavis@ +1 212 915 2577 Media Relations Contact Virginia Amann ENTENTE Network of Companies virginiaamann@ +1 833 500 0061 ext. 1 SOURCE: Protagonist Therapeutics View the original press release on ACCESS Newswire
